Dynamic Changes of Live/apoptotic Circulating Tumour Cells As Predictive Marker of Response to Sunitinib in Metastatic Renal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Sep 8

PMID 22955853

Citations 31

Authors

E Rossi

M Fassan

M Aieta

F Zilio

R Celadin

M Borin

A Grassi

L Troiani

U Basso

C Barile

T Sava

C Lanza

L Miatello

A Jirillo

M Rugge

S Indraccolo

M Cristofanilli

A Amadori

R Zamarchi

Affiliations

Soon will be listed here.

Abstract

Background: Recently, we developed an apoptotic assay for expanding the monitoring capabilities of the circulating tumour cells (CTC) test during therapy. An automated platform for computing CTCs was integrated with a mAb (M30) targeting a neoepitope disclosed by caspase cleavage at cytokeratin 18 in early apoptosis; we showed that live CTCs were associated with progression, consistent with enhanced cell migration and invasion. The test was first applied here to mRCC.

Methods: Live/apoptotic CTCs changes were measured in mRCC patients receiving first-line Sunitinib and compared with circulating endothelial cell (CEC) levels.

Results: The presence of EpCAM-positive, live CTCs predicts progression in individual mRCC patient, being associated with distant metastasis under first-line Sunitinib. Synchronous detection of CTCs and CEC levels discloses for the first time an association between their dynamic changes and outcome: a rapid increase of the CEC number as early as the first cycle of therapy is associated with CTC decrease in non-progressed patients, whereas a delayed response of CECs is related to higher CTC values in the progressed group indicating treatment failure.

Conclusion: We demonstrated that a delayed response to antiangiogenic treatment indicated by persistent detection of CECs correlates with persistent live CTCs and more aggressive disease.

Citing Articles

Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.

Szerenyi D, Jarvas G, Guttman A Molecules. 2025; 30(5).

PMID: 40076201 PMC: 11901967. DOI: 10.3390/molecules30050976.

Liquid biopsy for Renal Cell Carcinoma: A comprehensive review of techniques, applications, and future prospects.

Jani C, Abdallah N, Tan A, McKay R Kidney Cancer. 2025; 8(1):205-225.

PMID: 39886007 PMC: 11781563. DOI: 10.1177/24684570241303346.

Association of circulating tumor cell-white blood cell clusters with survival outcomes in patients with colorectal cancer after curative intent surgery.

Xu Y, Zhang Q, Xu Z, Xie Q, Ding W, Liu H BMC Gastroenterol. 2022; 22(1):503.

PMID: 36474175 PMC: 9727915. DOI: 10.1186/s12876-022-02603-4.

HMMR promotes peritoneal implantation of gastric cancer by increasing cell-cell interactions.

Yang M, Chen B, Kong L, Chen X, Ouyang Y, Bai J Discov Oncol. 2022; 13(1):81.

PMID: 36002694 PMC: 9402864. DOI: 10.1007/s12672-022-00543-9.

Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.

Basso U, Facchinetti A, Rossi E, Maruzzo M, Conteduca V, Aieta M Oncologist. 2021; 26(9):740-750.

PMID: 34077597 PMC: 8417856. DOI: 10.1002/onco.13842.

References

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

Rowand J, Martin G, Doyle G, Miller M, Pierce M, Connelly M . Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A. 2007; 71(2):105-13. DOI: 10.1002/cyto.a.20364. View

Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick D . Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med. 2007; 131(8):1290-7. DOI: 10.5858/2007-131-1290-IAOCRC. View

Rini B, Cohen D, Lu D, Chen I, Hariharan S, Gore M . Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103(9):763-73. PMC: 3086879. DOI: 10.1093/jnci/djr128. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Hutson T, Davis I, Machiels J, de Souza P, Rottey S, Hong B . Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 28(3):475-80. DOI: 10.1200/JCO.2008.21.6994. View

Visvader J, Lindeman G . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-68. DOI: 10.1038/nrc2499. View

Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H . Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009; 69(6):2506-13. PMC: 2664264. DOI: 10.1158/0008-5472.CAN-08-4323. View

Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli G . Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995; 1(12):1279-83. DOI: 10.1038/nm1295-1279. View

10.

Seligson D, Pantuck A, Liu X, Huang Y, Horvath S, Bui M . Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004; 10(8):2659-69. DOI: 10.1158/1078-0432.ccr-1132-03. View

11.

Mcdermott D, Regan M, Clark J, Flaherty L, Weiss G, Logan T . Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 23(1):133-41. DOI: 10.1200/JCO.2005.03.206. View

12.

Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M . M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010; 16(21):5233-43. DOI: 10.1158/1078-0432.CCR-10-1449. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Bidard F, Mathiot C, Degeorges A, Etienne-Grimaldi M, Delva R, Pivot X . Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol. 2010; 21(9):1765-1771. DOI: 10.1093/annonc/mdq052. View

15.

Marshall F, Dietrick D, Baumgartner W, Reitz B . Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol. 1988; 139(6):1166-72. DOI: 10.1016/s0022-5347(17)42848-5. View

16.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

17.

Patil S, Figlin R, Hutson T, Michaelson M, Negrier S, Kim S . Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2010; 22(2):295-300. DOI: 10.1093/annonc/mdq342. View

18.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

19.

van der Gun B, Melchers L, Ruiters M, de Leij L, McLaughlin P, Rots M . EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010; 31(11):1913-21. DOI: 10.1093/carcin/bgq187. View

20.

Sastre J, Maestro M, Puente J, Veganzones S, Alfonso R, Rafael S . Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19(5):935-8. DOI: 10.1093/annonc/mdm583. View